Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Trends in Biochemical Sciences|March 20, 2013
The chaperone Hsp90: changing partners for demanding clientsAlina Röhl, Julia Rohrberg, Johannes BuchnerMicropublication Biology|April 25, 2024
Changes in spindle morphology driven by TPX2 overexpression in MYC-driven breast cancer cellsGuadalupe Pena, Julia Rohrberg, Andrei Goga, et al.Expert Review of Medical Devices|July 4, 2026
Review of regulatory requirements for benefit - risk assessment for medical devices: uncovering existing methodologiesElena Scheller, Julia Rohrberg, Michael D'Agosto, et al.Molecular Cell|September 12, 2017
The Plasticity of the Hsp90 Co-chaperone SystemPriyanka Sahasrabudhe, Julia Rohrberg, Maximillian M Biebl, et al.FEBS Letters|April 15, 2008
Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMRJulia Rohrberg, Rolf Sachs, Grit Lodderstedt, et al.Nature Structural & Molecular Biology|September 6, 2011
Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53Franz Hagn, Stephan Lagleder, Marco Retzlaff, et al.Proceedings of the National Academy of Sciences of the United States of America|September 18, 2013
Regulated structural transitions unleash the chaperone activity of αB-crystallinJirka Peschek, Nathalie Braun, Julia Rohrberg, et al.Journal of Molecular Biology|October 30, 2012
The regulatory domain stabilizes the p53 tetramer by intersubunit contacts with the DNA binding domainMarco Retzlaff, Julia Rohrberg, Natascha Jennifer Küpper, et al.Cell Reports|March 12, 2020
MYC Dysregulates Mitosis, Revealing Cancer VulnerabilitiesJulia Rohrberg, Daniel Van de Mark, Meelad Amouzgar, et al.Nature Medicine|November 8, 2016
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expressionDai Horiuchi, Roman Camarda, Alicia Y Zhou, et al.Pageof 2